U.S. Upstream Bioprocessing Market

FUJIFILM Biotechnologies opened its Holly Springs, North Carolina site on 24 September 2025 with eight 20,000-litre bioreactors, 160,000 litres of cell culture capacity, and plans for eight more, in a project valued at USD 3.2 billion, according to Fujifilm. Johnson & Johnson and Regeneron both spoke at the opening. One site added about 6.5% to the U.S. culture volume that this report counts. The U.S. upstream bioprocessing market covers the cell culture media and supplements, bioreactors and fermenters, single-use upstream bags and assemblies, cell line development services and upstream sensors and probes used to grow cells that make biologic medicines in the United States. Douglas Insights sizes it at USD 4.05 billion in 2025, from 2.46 million litres of installed culture capacity at USD 1,645 of upstream spend per litre, and at USD 8.62 billion in 2035, a revenue CAGR (compound annual growth rate) of 7.86%. The study sits in our healthcare and life sciences coverage and every figure follows the Douglas Insights research methodology.

Which suppliers dominate upstream bioprocessing, and how concentrated are they?

Thermo Fisher Scientific supplies the most U.S. upstream bioprocessing value, about 21.4% of 2025 value or USD 866.0 million, Douglas Insights estimates. With Danaher’s Cytiva and Sartorius, the top three hold 49.8%.

Thermo Fisher’s lead rests on media volume and a broad single-use line. Its Life Sciences Solutions segment reported USD 10,374 million of 2025 revenue in its fourth-quarter results filed with the SEC. Danaher’s Biotechnology segment, home to Cytiva, reported USD 7,293 million in its 2025 results of 28 January 2026. Sartorius reported EUR 2,865 million of Bioprocess Solutions sales in its preliminary 2025 results, and Merck KGaA EUR 3,785 million in Process Solutions in its 2025 annual report.

The top two hold 40.0% of U.S. upstream bioprocessing value because switching a qualified medium or bioreactor bag after a drug is approved needs a regulatory filing, so incumbents keep their place for the life of the product. Smaller suppliers win in niches: Repligen in perfusion retention, Eppendorf in bench-scale development, and cell line developers sized in our Cell Line Development Market report.

Which U.S. upstream bioprocessing product earns most: media, bioreactors, single-use bags, cell lines or probes?

Cell culture media and supplements earn most, 36.8% of 2025 U.S. upstream bioprocessing value, USD 1.49 billion, because every batch consumes them. Single-use upstream bags and assemblies grow fastest, 10.20% a year to USD 2.24 billion.

Media lead because a 20,000-litre antibody batch can consume several thousand kilograms of powder and liquid feeds, and chemically defined media for high-titer processes sell at a premium. Their value grows 7.00% a year to USD 2.93 billion, a little below litre growth plus price, as higher titers cut media per gram. Bioreactors and fermenters, USD 946.9 million, grow 6.40% a year because stainless trains last 20 years or more.

Single-use upstream bags and assemblies, USD 849.8 million, grow 10.20% a year because every batch in a single-use bioreactor needs a new bag. Cell line development services hold USD 412.8 million and grow 8.00% a year with bispecific and antibody-drug conjugate (ADC) pipelines. Upstream sensors and probes, USD 348.0 million, grow 8.30% a year as process analytical technology spreads to continuous lines.

How do mammalian, microbial and CDMO demand split U.S. upstream bioprocessing spending?

Mammalian cell culture takes 84.0% of 2025 U.S. upstream bioprocessing value, USD 3.40 billion, because antibodies dominate the biologics pipeline. Drug sponsors buy 58.0% of value and contract manufacturers 33.0%.

By cell type, microbial fermentation holds 11.0%, USD 445.1 million, for insulin analogues, enzymes and plasmid DNA, and insect and other cells 5.0%, USD 202.3 million, mostly for viral vectors and vaccines. By end user, biopharmaceutical companies spend USD 2.35 billion, contract development and manufacturing organisations (CDMOs) USD 1.34 billion and academic and research institutes USD 364.2 million. By workflow, Douglas Insights puts cell culture at 62.0% of value, USD 2.51 billion, media preparation at 26.5%, USD 1.07 billion, and cell separation, including perfusion retention, at 11.5%, USD 465.4 million.

Spend per litre differs sharply by buyer. A sponsor running a 15,000-litre stainless antibody train spends close to the USD 900 to 1,300 band, while a CDMO running many short campaigns in 2,000-litre single-use bioreactors replaces bags, sensors and tubing sets every batch and spends nearer USD 2,000 per litre. Academic and research institutes, at USD 364.2 million, buy bench bioreactors, small-volume media and cell line work rather than production volume, so their upstream bioprocessing spend tracks research grants, not drug approvals.

CDMOs are the fastest-growing buyers of upstream bioprocessing supplies because sponsors without their own plants, and those moving work out of China, rent U.S. capacity; that market is sized in our Biologics Outsourcing Market report.

Why are U.S. upstream bioprocessing culture litres growing 5.40% a year?

U.S. upstream bioprocessing culture capacity grows 5.40% a year, from 2.46 million litres in 2025 to 4.16 million in 2035. Five forces add 5.90 points; onshoring supplies 2.40 and the antibody pipeline 1.50.

Onshoring new plants: 2.40 points

New U.S. plants add 2.40 points. Fujifilm’s 160,000 litres opened in September 2025. Eli Lilly announced a USD 5 billion plant in Goochland County, Virginia on 16 September 2025 to make active ingredients for its bioconjugate and monoclonal antibody portfolio, with about 650 jobs, Lilly said. Amgen’s second Holly Springs drug substance plant adds USD 1 billion to its earlier USD 550 million there, Fierce Pharma reported. Every new train needs media, bags and probes from its first batch.

Antibody and bispecific pipeline: 1.50 points

Antibodies add 1.50 points. Monoclonal antibodies, bispecifics and ADC payload carriers all grow in Chinese hamster ovary (CHO) cells, and late-stage U.S. pipelines keep adding commercial volume; the drug view is in our Therapeutic Monoclonal Antibodies Market report.

Work moving from China: 0.80 points

Reshoring from China adds 0.80 points as the BIOSECURE Act, enacted in December 2025, pushes federal contractors away from biotechnology companies of concern.

Cell and gene therapy and perfusion: 0.70 points

Advanced therapies add 0.70 points. Viral vector and HEK293 cell processes need perfusion media and retention devices that cost far more per litre than fed-batch.

Biosimilars: 0.50 points

Biosimilars add 0.50 points as copies of Stelara, Humira and newer antibodies move to U.S. contract lines. The five forces, 2.40 + 1.50 + 0.80 + 0.70 + 0.50, give 5.90 points before restraints.

What holds back upstream bioprocessing demand as titers rise and CDMO suites sit idle?

Two restraints remove 0.50 points from U.S. upstream bioprocessing litre growth, leaving 5.40% a year. Higher titers take 0.30 points and idle contract capacity 0.20 points.

Titers are the structural brake. A CHO process that once made 2 to 3 grams per litre now often makes 5 to 8, so the same tonnage of antibody needs fewer litres and less media per gram. Douglas Insights books this as 0.30 points of upstream bioprocessing litre growth lost each year, and as the reason media value grows slower than the market.

Idle CDMO suites remove 0.20 points. Contract makers added large stainless and single-use trains between 2020 and 2025, and some sat below full use while sponsors waited for approvals; until they fill, new orders for bioreactors slow. Validation also slows change: a supplier switch after approval needs comparability data, so new entrants struggle to win existing upstream bioprocessing lines.

Why does the Southeast grow fastest in U.S. upstream bioprocessing while the Mid-Atlantic and West Coast spend most?

The Mid-Atlantic and West Coast each spend USD 890.3 million, 22.0% of 2025 U.S. upstream bioprocessing value. The Southeast, led by North Carolina, grows fastest, 10.40% a year to USD 2.01 billion by 2035.

The Mid-Atlantic leads on old, large antibody plants and sponsor headquarters. The West Coast matches it with Genentech, Amgen and many biotech start-ups buying development-scale upstream bioprocessing supplies. New England, USD 789.1 million, buys the most per litre because its plants are small, single-use and often perfusion.

The Southeast grows fastest because Holly Springs alone hosts Fujifilm, Amgen and other biologics plants, and Virginia adds Lilly’s Goochland site. The Midwest grows 8.40% a year on Indiana and Ohio projects. The South and Mountain states, USD 303.5 million, grow 9.00% a year as Texas adds contract capacity. In the data table the row labelled Global holds the U.S. total, USD 4.05 billion in 2025.

What does upstream bioprocessing cost per bioreactor litre each year?

A U.S. biologics plant spent USD 1,645 per installed litre on upstream bioprocessing in 2025, Douglas Insights estimates, from about USD 900 in stainless trains to above USD 4,000 in perfusion suites. Spend rises 2.33% a year.

Spend per litre rises because the mix moves towards single-use and perfusion, where bags and media are bought for every batch, and because chemically defined media prices rise with inflation. Douglas Insights projects USD 1,683 per litre in 2026 and about USD 2,071 by 2035, against a global average of USD 1,512.6 in 2025.

The U.S. pays more per litre than the world average because more of its capacity is single-use and clinical-scale. Bench-scale and gas-mixed systems are sized in our Airlift Bioreactors Market report.

How do tariffs, BIOSECURE and FDA PreCheck rules shape U.S. upstream bioprocessing?

Three federal policies shape U.S. upstream bioprocessing: a 100% tariff on imported branded drugs announced on 25 September 2025, the BIOSECURE Act enacted in December 2025, and FDA PreCheck, launched on 7 August 2025 to speed new plants.

The tariff exempts companies that are building a U.S. plant, defined as having broken ground or being under construction, Foley Hoag reported, which pulled antibody projects forward. FDA PreCheck adds a facility readiness phase, with site design shared through a Type V drug master file, and an application phase for chemistry, manufacturing and controls, PharmTech reported; FDA noted only 11% of active ingredient makers are in the U.S.

The BIOSECURE Act became law on 18 December 2025 as section 851 of the fiscal 2026 National Defense Authorization Act, Akin Gump reported. It bars federal contracts with firms that use biotechnology equipment or services from a company of concern; the first list is due within a year and contracts signed earlier are protected for five years after final rules. Douglas Insights books BIOSECURE as 0.80 points of U.S. upstream bioprocessing litre growth and treats the tariff as part of the 2.40-point onshoring driver.

What if onshoring stalls: where does the U.S. upstream bioprocessing forecast land in 2035?

The U.S. upstream bioprocessing market ends 2035 between USD 7.03 billion and USD 10.3 billion across our three cases, around a base of USD 8.62 billion. The pace of new U.S. plants sets most of the spread.

In the slower case tariff threats fade, announced plants are delayed and titer gains cut litre needs faster. In the faster case most announced antibody plants run by 2030 and BIOSECURE moves large contracts out of China. One extra point of yearly litre growth adds USD 853.7 million to 2035 U.S. upstream bioprocessing value.

Our 7.86% base sits close to the 7.80% North America rate in the Douglas Insights upstream bioprocessing market study, below its 8.61% world rate, because Asia Pacific adds capacity faster.

Douglas Exclusive: the U.S. Upstream Onshoring Litre Ledger

The U.S. Upstream Onshoring Litre Ledger is a Douglas Insights model built from 11 sourced inputs, 7 company filings or releases and 4 federal actions, setting each dated event against the culture litres and upstream spend it adds.

The finding, a Douglas Insights estimate: the Southeast holds 18.5% of 2025 U.S. upstream bioprocessing value but supplies 27.4% of the USD 4.62 billion that sub-regions add by 2035, more than any other. Fujifilm’s first phase alone equals about 6.5% of 2025 U.S. culture litres, and a second phase of the same size would add as much again. The onshoring wave lands in North Carolina and Virginia first.

How does the methodology turn 2.46 million litres into USD 4.05 billion of upstream bioprocessing?

Our methodology multiplies 2.46 million litres of installed U.S. culture capacity in 2025 by USD 1,645 of upstream spend per litre to reach USD 4.05 billion. Litres come from six sub-region plant builds; spend per litre from three plant types.

The model covers 6 sub-regions, 5 products, 3 cell types, 3 end users and 3 plant types, and uses 63 data points, 11 sourced and 52 modelled. Arithmetic: 2.46 million x USD 1,645 = USD 4.047 billion; 4.047 x (1.0540 x 1.0233)^10 = 8.62, or USD 8.62 billion. Litres reach 2.59 million in 2026 and 4.16 million in 2035.

Two cross-checks agree. First, our USD 4.05 billion is 90.0% of the USD 4.49 billion North America row and 33.1% of the USD 12.21 billion world total in the Douglas Insights global study. Second, our Thermo Fisher and Cytiva estimates, USD 866.0 million and USD 752.7 million, are 8.3% and 10.3% of their disclosed Life Sciences Solutions and Biotechnology segment revenues, consistent with U.S. upstream being a minority of those global segments.

Sources

1. FUJIFILM Holdings Fujifilm opens Holly Springs large-scale cell culture site (2025)
2. Eli Lilly and Company Lilly announces plans to build USD 5 billion manufacturing facility in Virginia (2025)
3. Thermo Fisher Scientific / SEC Fourth quarter and full year 2025 results (Form 8-K exhibit) (2026)
4. Danaher Fourth quarter and full year 2025 results (2026)
5. Sartorius Preliminary full-year results 2025 (2026)
6. Merck KGaA Annual Report 2025, Life Science (2026)
7. Akin Gump BIOSECURE Act becomes law (2025)
8. PharmTech FDA moves to strengthen drug supply chain with PreCheck program (2025)
9. Foley Hoag 100% US tariff on branded or patented drugs effective 1 October 2025 (2025)
10. Fierce Pharma Amgen rolls out USD 1B investment to build new drug substance plant in NC (2024)

What counts in the U.S. upstream bioprocessing market, and what is excluded?

The U.S. upstream bioprocessing market counts revenue from upstream products and services used to grow cells for biologics in the United States. Downstream purification, fill-finish, analytical testing and contract manufacturing fees stay out.

The by-product split covers cell culture media and supplements, bioreactors and fermenters, single-use upstream bags and assemblies, cell line development services, and upstream sensors and probes. The by-workflow split covers media preparation, cell culture and cell separation. The by-cell-type split covers mammalian cells, microbial cells, and insect and other cells. The by-end-user split covers biopharmaceutical companies, CDMOs, and academic and research institutes. The by-sub-region split covers the Mid-Atlantic, West Coast, New England, Southeast, Midwest, and South and Mountain states. Chromatography resins, filters for purification, and contract manufacturing fees are excluded from this upstream bioprocessing sizing.